 COVALENT-111, a Phase III clinical trial in patients with type 2 diabetes, already underway in Canada, will now activate sites in the US As previously reported, the Phase I portion of COVALENT-111 has been completed, with BMF-219 demonstrating a favorable safety, pharmacokinetics PK and pharmacodynamics PD profile Ongoing Phase II portion is evaluating BMF-219s long-term ... The post Biomea Fusion Announces FDA Clearance of Investigational New Drug IND Application for Covalent Menin In... 